Smartin Bio is a Ulsan-based South Korean biotechnology company founded in 2019 as a spin-off from UNIST research on mitochondrial biology. It develops first-in-class therapeutics built on inhibitors of the mitochondrial chaperone TRAP1, with pipeline programs targeting diabetic retinopathy - including a sustained-release ocular implant intended to replace frequent anti-VEGF injections - as well as relapsed or refractory AML and triple-negative breast cancer. The company collaborates with Hanlim Pharm and the MD Anderson Cancer Center on non-clinical development, GMP manufacturing and global regulatory strategy.
1
Round
1
Industry
4
Tags
Oct 21, 2026
Latest raise
Funding activity · 1 round
Oct 21, 2026
KRW 200M
Seed
Led by Hanlim Pharm (한림제약)
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
